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Background:  Selexipag, an orally available, selective prostacyclin (PGI2) receptor (IP receptor) agonist, significantly decreased 
pulmonary vascular resistance in patients with pulmonary arterial hypertension (PAH) in a phase 2 clinical trial. Selexipag is structurally 
different from PGI2. Reduced clinical efficacy of PGI2 analogs can be observed in patients with PAH following repeated or continuous 
administration via parenteral routes, in a process called tachyphylaxis. This study used a rat model to investigate tachyphylaxis in response 
to repeated oral administration of selexipag.
methods:  Spontaneously hypertensive rats (SHRs) were implanted with telemetry recording systems and mean arterial blood pressure 
(MAP) and heart rate (HR) were monitored. Selexipag was administered either by oral gavage (b.i.d.), or incorporated in normal rat chow 
(food admix). The effects of the PGI2 analog treprostinil, administered via continuous i.v. infusion, were measured in comparison.
results:  A sub-maximal dose of selexipag (oral gavage, 10 mg/kg, b.i.d.) decreased MAP in SHRs (maximum decrease: 21 ± 6 mmHg) 
in a reproducible manner upon each administration of drug over the duration of the experiment (5 days). Selexipag (food admix, 10, 
30, 100 and 300 mg/kg/day) caused a dose-dependent reduction in MAP. The effect of selexipag was maintained for 4 days at each 
dose level. Plasma concentrations of ACT-333679, the active metabolite of selexipag, were increased at each dose level. A submaximal 
dose of selexipag (food admix, 100 mg/kg/day) decreased MAP for up to 10 days. MAP returned to pre-drug levels on cessation of drug 
administration in both food admix experiments. Continuous infusion of an equi-effective dose of the PGI2 analog treprostinil (30 µg/kg/
hr, i.v.) caused a transient reduction in MAP, which returned to pre-drug levels within 36 hours, despite the continued presence of drug in 
plasma.
conclusion:  Repeated oral administration of selexipag does not induce tachyphylaxis in a rat model of systemic hypertension, whereas 
the response to continuous infusion of an equi-effective dose of a PGI2 analog is not maintained. Long-term use of selexipag may be 
associated with maintained efficacy.
